Showing results (1-10 of 153) with videos related to
Sort By:
Pageof 16
Japanese Journal of Clinical Oncology|August 14, 2018
Proteasome inhibitors for multiple myelomaKiyoshi Okazuka, Tadao IshidaFuture Oncology (London, England)|November 4, 2022
Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in JapanShinsuke Iida, Mayuko Nakakoji, Dionysis Spanopoulos, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|July 6, 2018
[Carfilzomib, lenalidomide, and dexamethasone therapy for refractory and relapsed multiple myeloma: a single-center study of 29 patients]Kiyoshi Okazuka, Tadao Ishida, Kota Sato, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 7, 2020
[Elotuzumab treatment for a multiple myeloma patient relapsing after allogenic stem cell transplantation]Kota Sato, Nobuhiro Tsukada, Junichiro Nashimoto, et al.European Journal of Haematology|November 17, 2019
The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myelomaKiyoshi Okazuka, Tadao Ishida, Junichiro Nashimoto, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 8, 2017
[IgE-κ type multiple myeloma achieving complete response with novel agents]Tomomi Takei, Tadao Ishida, Masahiro Ikeda, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 8, 2019
[Clinical characteristics of young multiple myeloma patients: a single-center analysis of 30 patients]Yumiko Yoshiki, Nobuhiro Tsukada, Junichiro Nashimoto, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 10, 2019
[Efficacy of plerixafor in autologous peripheral blood stem cell collection]Takao Yogo, Nobuhiro Tsukada, Junichiro Nashimoto, et al.International Journal of Hematology|June 26, 2019
Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosisTakao Yogo, Kiyoshi Okazuka, Junichiro Nashimoto, et al.International Journal of Hematology|November 2, 2019
Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysisKazuhito Suzuki, Nobuhiro Tsukada, Noriko Nishimura, et al.Pageof 16